Leveraging Data to Predict Future Non-Adherence

Nearly 150 million people in the U.S. have at least one chronic illness, and as many as half fail to take their prescriptions appropriately.1,2

As a result, medication non-adherence leads to 125,000 deaths annually and costs the U.S. health care system up to $289 billion a year.3 Predictive analytics play a major role in health care through identifying medication non-adherence, improving clinical outcomes and reducing health care expenditures.

What is Predictive Analytics?

In modern health care, the integration of technology, data and predictive modeling has transformed chronic disease management and enabled a proactive approach to population health management. Predictive analytics forecast member-level adherence patterns using numerous data measures, including:

Complex disease states

Medication refill habits

Socio-geographic data

Behavioral information

Medication regimen complexity

In addition, plan sponsors can leverage other social determinants of health and demographic data to identify members at risk for medication non-adherence.

Seeing the Value of Predictive Analytics

Predictive analytics enable clinicians to view the overall population percentages identified as at risk, as well as ranking and prioritizing identified members who are at the highest risk of non-adherence. A plan sponsor’s case management team can then use this information to reach out to members in a proactive manner and provide educational information and support. Ultimately, this support can address gaps in care at an early stage or even preemptively, and avoid potential medical costs such as emergency room visits or hospitalizations down the road.

Providing a Solution

Our Predictive Analytics Reporting identifies and classifies members into risk groups of low, medium or high-risk, based on prescription history and past behaviors. Twelve months of each member’s claims history is analyzed for:

Number of prescribers, pharmacies and prescriptions

Controlled substances

Duplicate therapy instances

Proportion of days covered (PDC) for multiple medication categories

New starts to therapy

Late refills

Drug-age considerations

Socioeconomic and demographic factors

And more

All of these components play a role in predicting non-adherence. Plan sponsors receive customized reports with member-level data to help them determine the desired method of intervention and outreach.

Delivering Results

Proven valuable in optimizing member health outcomes, our Predictive Analytics for Non-Adherence tool has a high specificity of 95.6% in successfully predicting future non-adherence. With this level of precision, plan sponsors can rest assured they are receiving additional support that can address gaps in care early on and avoid costly medical expenses such as emergency room visits and hospital stays, while improving their member’s overall disease management.

Start seeing and experiencing the benefits of improved health and lower costs today. Ask your account representative about predictive analytics for non-adherence.

Irving D. Chronic Conditions in America: Price and Prevalence. RAND Corporation. https://www.rand.org/blog/rand-review/2017/07/chronic-conditions-in-america-price-and-prevalence.html. Published July 12, 2017. Accessed October 6, 2020.

Prevalence of Multiple Chronic Conditions Among US Adults, 2018. CDC. https://cdc.gov/pdc/issues/2020/20_130.htm. Published September 17, 2020. Accessed February 26, 2025.

Brody J. The Cost of Not Taking Your Medicine. The New York Times. https://www.nytimes.com/2017/04/17/well/the-cost-of-not-taking-your-medicine.htmlrref=collection%2Fsectioncollection%2Fhealth&action=click&contentCollection=health&region=stream&module=stream_unit&version=latest&contentPlacement=1&pgtype=sectionfront&_r=1. Published April 17, 2017. Accessed October 6, 2020.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

previous arrow
next arrow